The government of Canada has sanctioned a startup to export psychedelic substances for medical applications to Australia. Optimi Health Corp. has been appointed to transport pills containing psilocybin, an extract from magic mushrooms, and MDMA, as approved by the health department.
The growing demand surpasses the domestic magic mushrooms Ontario. Other countries are following Canada’s lead, beginning to investigate and authorize the medicinal usage of serotogenic compounds.
Confidently buy psychedelics online in Canada and tap into your innate potential through trustworthy sources.
[toc]Main Points
- Optimi Health, a Vancouver-based startup, has been given a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms for the treatment of chronic depression.
- The therapy consists of three sessions spaced over five to eight weeks, with each session lasting around eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based small business, plans to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain a first-mover advantage.
Seven firms have exported psilocybin, MDMA, or both, but only for the purpose of clinical trials. A spokesperson from Canada’s health department couldn’t confirm if these exports were for regular patient treatment and chose not to reveal the companies due to security reasons.
This accomplishment situates Optimi among a handful of global suppliers, with the current market favoring clinical rather than recreational use.
What Does the Pill Contain?
Although the company hasn’t disclosed the specific mushroom species used in the pill, they work with various strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for cultivating, testing, and extracting its psychedelic mushrooms. This quaint locale, home to roughly 3,000 inhabitants, is situated a three-hour journey east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
It’s estimated that 1 in every 5 Australians, aged between 16 and 85, may face a mental health challenge. PTSD (post-traumatic stress disorder) is expected to impact 11% of Australians in their lifetime, while anxiety disorders are common among 17% of the population.
While there are numerous ways to treat mental health issues, not all are effective for everyone. Those who don’t respond to certain treatments may struggle to find a method that helps, making them more susceptible to their illness.
The Procedure Unveiled
Australia has blazed a trail by incorporating psilocybin into treatment plans, allowing licensed psychiatrists to use this controlled substance for treating resistant PTSD and depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic use. The TGA confirmed these substances are safe for use in a medically supervised setting for patients with severe mental disorders.
This change is a game-changer for many mental health professionals and researchers. The use of these substances will be strictly monitored; it’s not just about taking a pill and departing.
The treatment regimen typically consists of three sessions over a span of five to eight weeks. Each session endures approximately eight hours, with the therapist present with the patient throughout the duration.
Canada’s Role in Psilocybin Research
Canada has stepped into the limelight as a leading center for psilocybin research, significantly expanding our understanding of this substance. Health Canada, in collaboration with several institutions, is leading the quest to uncover psilocybin’s therapeutic potential for treating various mental health conditions.
Research institutions are no longer required to label these substances illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow shrooms for research purposes.
The increased accessibility of substances historically considered harmful enables researchers to deepen their understanding of their potential benefits to a broad range of individuals.
A Recurrent Trend
The 1950s marked the first acknowledgment of the potential within this field to tackle mental health problems and substance abuse, including alcohol addiction. This initial research, spearheaded by English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, took place at the Weyburn Mental Hospital in Saskatchewan. Significant progress was made during the tenure of Premier Tommy Douglas, who provided the medical community with substantial autonomy to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer pursued investigations using LSD, mescaline, and peyote as potential alternatives to the extreme measures of electroshock and lobotomy. This research expanded in unforeseen ways, with both advocating for medical professionals, nursing staff, and ancillary staff to experiment with these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to ascertain the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Primary Investigator | Project Budget |
| A randomized controlled trial | Psychological distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enhance the understanding of the therapeutic potential of controlled substances. It has been made possible by the Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, also known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The therapeutic approach includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical evaluation of an illegal
Demystifying Psilocybin
Psilocybin is a naturally-derived psychedelic compound found within certain mushroom species. Once ingested, it transforms into psilocin, an active compound that activates serotonin 5-HT2a receptors in the brain’s cortical pyramidal cells, which are crucial for mental processing.
Scientists are currently studying psilocybin for its potential benefits in treating depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual growth.
How Does it Help with Depression, PTSD, and More?
The active component of psilocybin affects several brain areas, making it potentially beneficial for various mental health conditions. Encouraging results have been reported from patients in Canada and Australia who have undergone treatment with minimal side effects, such as temporary anxiety or increased blood pressure.
Effects on Neurobiology
- Activation of Serotonin Receptors: Psilocybin partially stimulates serotonin receptors, especially the 5-HT2A subtype, which plays a crucial role in emotional processing and mood regulation.
- Modulation of the Default Mode Network (DMN): Psilocybin reduces activity within the DMN, which promotes introspection, disrupts rigid thought patterns, and encourages emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The substance’s antidepressant effects stem from its interaction with the brain’s prefrontal and limbic regions, including the amygdala. In depressive states, individuals often show decreased reaction to emotional stimuli. Psilocybin increases the response to positive emotional stimuli in the right amygdala and normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Creation of Positive Emotional States: Psilocybin can induce feelings of joy, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic journey may allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it may contribute to long-lasting benefits, such as increased happiness, improved life satisfaction, and spiritual growth.
What Can Be Found at Your Local Magic Mushroom Shop?
Interested in how this substance might affect your mental health? Browse through magic mushroom stores to find a suitable product.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, triggers creative thinking, and boosts productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Enhances wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clarity, creativity, and concentration. Contains a powerful mixture of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acceptance of Psilocybin
Canada is not the only country supporting the use of magic mushrooms for mental health issues. Countries like Australia are also endorsing these hallucinogens to tackle conditions like depression and PTSD. They are procuring top-quality psychedelic capsules from trusted sources. With proper supervision, patients can significantly improve their life quality. Psychedelic Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potential in enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is beneficial for treating depression and addiction.
Conversely, MDMA promotes empathy and is effective in PTSD treatment. It has potential in boosting emotional processing and
Despite being classified as a controlled substance, this treatment has shown therapeutic potential.
Is this treatment available to all Australians?
Not necessarily. In Australia, an individual’s eligibility for this treatment is determined after a comprehensive evaluation. This assessment takes into account various factors such as existing heart conditions and a history of psychosis. Only patients who have not responded to conventional treatments for disorders such as depression, anxiety, and PTSD can access this treatment.
What implications arise from Canada’s export of mushrooms?
Canada’s move to dominate the psychedelics market, much like its approach with cannabis, could lead to an influx of companies producing high-quality products. This could position Canada at the forefront of the hallucinogens market, boost its economy, and simplify access to these treatments for other countries. It would also discourage countries from acquiring their hallucinogens from illegal dispensaries or suppliers, thereby enhancing safety.
Articles That Might Interest You:
